International Biotechnology Trust Stock EBITDA
| IBT Stock | 704.00 4.00 0.57% |
International Biotechnology Trust fundamentals help investors to digest information that contributes to International Biotechnology's financial success or failures. It also enables traders to predict the movement of International Stock. The fundamental analysis module provides a way to measure International Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to International Biotechnology stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 39.6 M | 19.8 M |
International | EBITDA |
International Biotechnology Trust Company EBITDA Analysis
International Biotechnology's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current International Biotechnology EBITDA | 39.55 M |
Most of International Biotechnology's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, International Biotechnology Trust is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
International Ebitda
Ebitda |
|
According to the company disclosure, International Biotechnology Trust reported earnings before interest,tax, depreciation and amortization of 39.55 M. This is 99.94% lower than that of the Capital Markets sector and 96.01% lower than that of the Financials industry. The ebitda for all United Kingdom stocks is 98.99% higher than that of the company.
International EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses International Biotechnology's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of International Biotechnology could also be used in its relative valuation, which is a method of valuing International Biotechnology by comparing valuation metrics of similar companies.International Biotechnology is currently under evaluation in ebitda category among its peers.
International Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, International Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to International Biotechnology's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
International Fundamentals
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0806 | ||||
| Profit Margin | 0.91 % | ||||
| Operating Margin | 1.00 % | ||||
| Current Valuation | 271.71 M | ||||
| Shares Outstanding | 36.28 M | ||||
| Shares Owned By Insiders | 1.39 % | ||||
| Shares Owned By Institutions | 44.43 % | ||||
| Price To Book | 0.90 X | ||||
| Price To Sales | 6.70 X | ||||
| Revenue | 40.14 M | ||||
| Gross Profit | (13.58 M) | ||||
| EBITDA | 39.55 M | ||||
| Net Income | 38.88 M | ||||
| Total Debt | 22.83 M | ||||
| Book Value Per Share | 7.66 X | ||||
| Cash Flow From Operations | 45.35 M | ||||
| Earnings Per Share | 1.02 X | ||||
| Beta | 0.21 | ||||
| Market Capitalization | 255.4 M | ||||
| Total Asset | 308.15 M | ||||
| Retained Earnings | (54.03 M) | ||||
| Annual Yield | 0.04 % | ||||
| Net Asset | 308.15 M | ||||
| Last Dividend Paid | 0.28 |
About International Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze International Biotechnology Trust's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of International Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of International Biotechnology Trust based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in International Stock
International Biotechnology financial ratios help investors to determine whether International Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in International with respect to the benefits of owning International Biotechnology security.